Simplifying checkpoint inhibitor delivery through in vivo generation of synthetic DNA-encoded monoclonal antibodies (DMAbs)

Checkpoint inhibitors (CPI) have revolutionized the treatment of many solid tumors. However, difficulties in production, stability, the requirement of frequent high doses for antibody administration and long intravenous administration are recurring issues. Synthetically designed DNA-encoded monoclon...

Descripción completa

Detalles Bibliográficos
Autores principales: Perales-Puchalt, Alfredo, Duperret, Elizabeth K., Muthumani, Kar, Weiner, David B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343757/
https://www.ncbi.nlm.nih.gov/pubmed/30713599
http://dx.doi.org/10.18632/oncotarget.26535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343757/
https://www.ncbi.nlm.nih.gov/pubmed/30713599
http://dx.doi.org/10.18632/oncotarget.26535

Ejemplares similares